Tecan and TAP Biosystems Announces a Co-Marketing Agreement
News Nov 01, 2012
Tecan and TAP Biosystems have announced a co-marketing agreement to further expand the automated 3D cell culture capabilities of the Freedom EVO® liquid handling platform.
Automation of TAP’s collagen-based RAFT™ cell culture system will allow scientists to quickly and conveniently create 3D cell cultures in a 96-well, SBS-format.
The RAFT 3D cell culture system uses biologically relevant concentrations of collagen matrix to ensure cells grow and proliferate in an environment closely resembling the native tissue.
The Freedom EVO workstation is configured with a number of modules, including reagent and microplate cooling units and a heated shaking device, to provide fully automated preparation and maintenance of RAFT cell cultures.
This ensures rapid, reliable creation of consistent and reproducible 3D cell cultures, offering walkaway processing for a wide range of cell biology applications.
Kevin Moore, Head of Applications and Solutions at Tecan, commented: “We are pleased to further expand our automated 3D cell culture portfolio to include the RAFT system. Working together with TAP Biosystems, we will be able to offer a complete solution for automated 3D cell culture.”
Dr Grant Cameron, TAP Biosystems’ RAFT Development Director, added: “RAFT is rapidly becoming a core secondary screening technology within drug discovery. This exciting collaboration will enable researchers to expand the power of the realistic collagen environment of RAFT, with substantially increased throughput to meet their cell-based screening requirements.”
U.S. Study of Dapivirine Ring in Lactating Women Finds Little Drug Gets Into Breast MilkNews
The antiretroviral drug dapivirine that is released from an experimental vaginal ring to protect against HIV is absorbed in very low concentrations into breastmilk.READ MORE
CRISPR Reveals New Targets for Promising Cancer DrugsNews
Novel screening method identifies new drug targets that could potentially enhance the effectiveness of PD-1 checkpoint inhibitors, a promising new class of cancer immunotherapy.READ MORE
Comments | 0 ADD COMMENT
EMBL Conference: European Conference of Life Science Funders and Foundations
Apr 19 - Apr 20, 2018
EMBL Course: Transgenic Animals - Micromanipulation Techniques
Apr 10 - Apr 11, 2018
EMBO Practical Course: Extracellular Vesicles: From Biology to Biomedical Applications
Apr 09 - Apr 13, 2018
EMBO | EMBL Symposium: Tissue Self-Organisation: Challenging the Systems
Mar 11 - Mar 14, 2018